Assessing the Role of DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio in Rheumatoid Arthritis

Abstract EN

Rheumatoid arthritis (RA) is a disease of chronic systemic inflammation (SI).

In the present study, we used four datasets to explore whether methylation-derived neutrophil-to-lymphocyte ratio (mdNLR) might be a marker of SI in new onset, untreated, and treated prevalent RA cases and/or a marker of treatment response to the tumour necrosis factor inhibitor (TNFi) etanercept.

mdNLR was associated with increased odds of being a new onset RA case (OR = 2.32, 95% CI = 1.95–2.80, P<2×10−16) and performed better in distinguishing new onset RA cases from controls compared to covariates: age, gender, and smoking status.

In untreated preclinical RA cases and controls, mdNLR at baseline was associated with diagnosis of RA in later life after adjusting for batch (OR = 4.30, 95% CI = 1.52–21.71, P=0.029) although no association was observed before batch correction.

When prevalent RA cases were treated, there was no association with mdNLR in samples before and after batch correction (OR = 0.34, 95% CI = 0.05–1.82, P=0.23), and mdNLR was not associated with treatment response to etanercept (OR = 1.10, 95% CI = 0.75–1.68, P=0.64).

Our results indicate that SI measured by DNA methylation data is indicative of the recent onset of RA.

Although preclinical RA was associated with mdNLR, there was no difference in the mean mdNLR between preclinical RA cases and controls.

mdNLR was not associated with RA case status if treatment for RA has commenced, and it is not associated with treatment response.

In the future, mdNLR estimates may be used as a valuable research tool to reliably estimate SI in the absence of freshly collected blood samples.